Neutralizing Activity against BQ.1.1, BN.1, and XBB.1 in Bivalent COVID-19 Vaccine Recipients: Comparison by the Types of Prior Infection and Vaccine Formulations

Neutralizing Activity against BQ.1.1, BN.1, and XBB.1 in Bivalent COVID-19 Vaccine Recipients: Comparison by the Types of Prior Infection and Vaccine Formulations

Bivalent COVID-19 vaccines that contain BA.1 or BA.4/BA.5 have been introduced worldwide in response to pandemic waves of Omicron subvariants. This prospective cohort study was aimed to compare neutralizing antibodies (Nabs) against Omicron subvariants (BA.1, BA.5, BQ.1.1, BN.1, and XBB.1) before an...

Full description

Bibliographic Details
Main Authors: Hak-Jun Hyun, Min-Joo Choi, Eliel Nham, Hye Seong, Jin-Gu Yoon, Ji-Yun Noh, Hee-Jin Cheong, Woo-Joo Kim, Sun-Kyung Yoon, Se-Jin Park, Won-Seok Gwak, June-Woo Lee, Byoung-Guk Kim, Joon-Young Song
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Vaccines
Subjects:
SARS-CoV-2
bivalent vaccine
Omicron
neutralizing antibody
reactogenicity
Online Access:https://www.mdpi.com/2076-393X/11/8/1320

Internet

https://www.mdpi.com/2076-393X/11/8/1320

Similar Items